nach oben

Current Gastroenterology Reports

Erschienen in:

07.12.2023

Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract in Cystic Fibrosis

verfasst von: Dhiren Patel, Folashade Jose, Jason Baker, Baha Moshiree

Erschienen in: Current Gastroenterology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To discuss all the various motility disorders impacting people with Cystic Fibrosis (PwCF) and provide diagnostic and management approaches from a group of pediatric and adult CF and motility experts and physiologists with experience in the management of this disease.

Recent Findings

Gastrointestinal (GI) symptoms coexist with pulmonary symptoms in PwCF regardless of age and sex. The GI manifestations include gastroesophageal reflux disease, esophageal dysmotility gastroparesis, small bowel dysmotility, small intestinal bacterial overgrowth syndrome, distal idiopathic obstruction syndrome, constipation, and pelvic floor disorders. They are quite debilitating, limiting the patients’ quality of life and affecting their nutrition and ability to socialize. This genetic disorder affects many organ systems and is chronic, potentially impacting fertility and future family planning, requiring a multidisciplinary approach.

Summary

Our review discusses the treatments of motility disorders in CF, their prevalence and pathophysiology. We have provided a framework for clinicians who care for these patients that can help to guide their clinical management.

Moshiree B, Freeman AJ, Vu PT, Khan U, Ufret-Vincenty C, Heltshe SL, et al. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis. J Cyst Fibros. 2023;22(2):266–74.PubMedCrossRef

Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest. 2000;118(4):1214–7.PubMedCrossRef

Sabati AA, Kempainen RR, Milla CE, Ireland M, Schwarzenberg SJ, Dunitz JM, et al. Characteristics of gastroesophageal reflux in adults with cystic fibrosis. J Cyst Fibros. 2010;9(5):365–70.PubMedCrossRef

Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, et al. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI. J Cyst Fibros. 2023;22(2):282–9.PubMedCrossRef

Jaudszus A, Zeman E, Jans T, Pfeifer E, Tabori H, Arnold C, et al. Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score). Patient. 2019;12(4):419–28.PubMedCrossRef

Woodley FW, Machado RS, Hayes D Jr, Di Lorenzo C, Kaul A, Skaggs B, et al. Children with cystic fibrosis have prolonged chemical clearance of acid reflux compared to symptomatic children without cystic fibrosis. Dig Dis Sci. 2014;59(3):623–30.PubMedCrossRef

Bongiovanni A, Manti S, Parisi GF, Papale M, Mule E, Rotolo N, et al. Focus on gastroesophageal reflux disease in patients with cystic fibrosis. World J Gastroenterol. 2020;26(41):6322–34.PubMedPubMedCentralCrossRef

Woodley FW, Hayes D Jr, Kopp BT, Moore-Clingenpeel M, Machado RS, Nemastil CJ, et al. Gastroesophageal reflux in cystic fibrosis across the age spectrum. Transl Gastroenterol Hepatol. 2019;4:69.PubMedPubMedCentralCrossRef

Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, et al. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. J Cyst Fibros. 2020;19(3):344–54.PubMedCrossRef

10.

Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516–54.PubMedPubMedCentralCrossRef

11.

Button BM, Roberts S, Kotsimbos TC, Levvey BJ, Williams TJ, Bailey M, et al. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant. 2005;24(10):1522–9.PubMedCrossRef

12.

DeVault KR, Castell DO, American College of G. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.PubMedCrossRef

13.

Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg. 2013;217(4):586–97.PubMedCrossRef

14.

Yadlapati R, Gyawali CP, Pandolfino JE, Participants CGCC. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022;20(5):984-94 e1.PubMedPubMedCentralCrossRef

15.

Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. Pediatr Pulmonol. 2013;48(6):556–62.PubMedCrossRef

16.

Sathe M, Moshiree B, Vu PT, Khan U, Heltshe SL, Romasco M, et al. Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY study. J Cyst Fibros. 2021;20(4):605–11.PubMedPubMedCentralCrossRef

17.

Sathe M, Moshiree B, Aliaj E, Lee M, Hudson J, Gifford A, et al. Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators. Pediatr Pulmonol. 2023;58(3):811–8.PubMedCrossRef

18.

Mertens V, Blondeau K, Pauwels A, Farre R, Vanaudenaerde B, Vos R, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci. 2009;54(5):972–9.PubMedCrossRef

19.

Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55(3):675–83.PubMedCrossRef

20.

Chini P, Toskes PP, Waseem S, Hou W, McDonald R, Moshiree B. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol. 2012;47(4):422–7.PubMedCrossRef

21.

Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225–33.PubMedCrossRef

22.

Corral JE, Dye CW, Mascarenhas MR, Barkin JS, Salathe M, Moshiree B. Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic review. Scientifica (Cairo). 2016;2016:2918139.PubMed

23.

Moshiree B, Potter M, Talley NJ. Epidemiology and Pathophysiology of Gastroparesis. Gastrointest Endosc Clin N Am. 2019;29(1):1–14.PubMedCrossRef

24.

Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–40.PubMedCrossRef

25.

Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini MS, Smyrk TC, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. 2011;140(5):1575-85 e8.PubMedCrossRef

26.

Murphy MS, Brunetto AL, Pearson AD, Ghatei MA, Nelson R, Eastham EJ, et al. Gut hormones and gastrointestinal motility in children with cystic fibrosis. Dig Dis Sci. 1992;37(2):187–92.PubMedCrossRef

27.

Cassilly D, Kantor S, Knight LC, Maurer AH, Fisher RS, Semler J, et al. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil. 2008;20(4):311–9.PubMedCrossRef

28.

Kloetzer L, Chey WD, McCallum RW, Koch KL, Wo JM, Sitrin M, et al. Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. Neurogastroenterol Motil. 2010;22(5):527–33, e117.PubMed

29.

Parkman HP, Hasler WL, Fisher RS, American GA. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–622.PubMedCrossRef

30.

Carlson DA, Gyawali CP, Khan A, Yadlapati R, Chen J, Chokshi RV, et al. Classifying esophageal motility by FLIP panometry: a study of 722 subjects with manometry. Am J Gastroenterol. 2021;116(12):2357–66.PubMedPubMedCentralCrossRef

31.

Ng C, Dellschaft NS, Hoad CL, Marciani L, Ban L, Prayle AP, et al. Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. J Cyst Fibros. 2021;20(4):591–7.PubMedCrossRef

32.

FDA. Domperidone, FDA IND 2021 [Available from: https://www.fda.gov/drugs/investigational-new-drug-ind-application/how-request-domperidone-expanded-access-use. Accessed 2021.

33.

Pitt HA, Mann LL, Berquist WE, Ament ME, Fonkalsrud EW, DenBesten L. Chronic intestinal pseudo-obstruction. Management with total parenteral nutrition and a venting enterostomy. Arch Surg. 1985;120(5):614–8.PubMedCrossRef

34.

Rahnemai-Azar AA, Rahnemaiazar AA, Naghshizadian R, Kurtz A, Farkas DT. Percutaneous endoscopic gastrostomy: indications, technique, complications and management. World J Gastroenterol. 2014;20(24):7739–51.PubMedPubMedCentralCrossRef

35.

Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335(4):290–1.PubMedCrossRef

36.

Tillman EM, Smetana KS, Bantu L, Buckley MG. Pharmacologic treatment for pediatric gastroparesis: a review of the literature. J Pediatr Pharmacol Ther. 2016;21(2):120–32.PubMedPubMedCentral

37.

Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92(6):976–80.PubMed

38.

Malik Z, Kataria R, Modayil R, Ehrlich AC, Schey R, Parkman HP, et al. Gastric per oral endoscopic myotomy (G-POEM) for the treatment of refractory gastroparesis: early experience. Dig Dis Sci. 2018;63(9):2405–12.PubMedCrossRef

39.

Schatz RA, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574–82.PubMedPubMedCentralCrossRef

40.

Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112(5):775–84.PubMedPubMedCentralCrossRef

41.

Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS ONE. 2017;12(5):e0174463.PubMedPubMedCentralCrossRef

42.

Furnari M, De Alessandri A, Cresta F, Haupt M, Bassi M, Calvi A, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. J Gastroenterol. 2019;54(3):261–70.PubMedCrossRef

43.

Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007;44(2):212–8.PubMedCrossRef

44.

Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–78.PubMedCrossRef

45.

Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078.PubMedPubMedCentralCrossRef

46.

Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.PubMedPubMedCentralCrossRef

47.

Burton SJ, Hachem C, Abraham JM. Luminal gastrointestinal manifestations of cystic fibrosis. Curr Gastroenterol Rep. 2021;23(3):4.CrossRef

48.

Moshiree B, Khan A, Jones ML, Singh S, Wahl C, Chuang E. S0507 SIBO diagnosis: clinical survey of practice patterns, unmet needs, and perception of a novel ingestible diagnostic capsule. Off J Am Coll Gastroenterol | ACG. 2020;115:S236–7.CrossRef

49.

Rao SS, Moshiree B, Lee N, Jones ML, Chuang E, Singh S. S1282 Evaluation of Smart Capsule Bacterial Detection System (SCBDS) assay and duodenal culture in subjects suspected of SIBO and undergoing upper endoscopy: interim analysis. Off J Am Coll Gastroenterol | ACG. 2020;115:S644.CrossRef

50.

De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol. 2007;293(3):G577–84.PubMedCrossRef

51.

Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925–34.PubMedCrossRef

52.

Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19(6):687–94.PubMedCrossRef

53.

Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motorcomplex in human gastrointestinal tract. Dig Dis Sci. 1986;31(2):157–61.PubMedCrossRef

54.

Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–45.PubMedCrossRef

55.

Gonzalez Z, McCallum R. Small bowel dysmotility, pseudoobstruction, and functional correlation with histopathology: lessons learned. Curr Gastroenterol Rep. 2020;22(3):14.PubMedCrossRef

56.

Lipton AB, Knauer CM. Pseudo-obstruction of the bowel. Therapeutic trial of metoclopramide. Am J Dig Dis. 1977;22(3):263-5

57.

Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction–a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35(1):48–55.PubMedCrossRef

58.

Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–7.PubMedCrossRef

59.

Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40(9):1892–901.PubMedCrossRef

60.

Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12(2):167–74.PubMedCrossRef

61.

Parthasarathy G, Ravi K, Camilleri M, Andrews C, Szarka LA, Low PA, Zinsmeister AR, Bharucha AE. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015;27(12):1736–46.PubMedPubMedCentralCrossRef

62.

O’Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis. 2010;12(6):540–8.PubMedCrossRef

63.

Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112–22.PubMed

64.

Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics. 1986;78(3):473–9.PubMedCrossRef

65.

Green J, Gilchrist FJ, Carroll W. Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018;6(6):CD012619.PubMed

66.

Ferec C, Cutting GR. Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect Med. 2012;2(12):a009480.PubMedPubMedCentralCrossRef

67.

Patel D, Mathews S, van Unen V, Chan JE, Al-Hammadi N, Borowitz D, et al. Impaired distal colonic pH in adults with cystic fibrosis. J Cyst Fibros. 2023;22(2):290–5.PubMedCrossRef

68.

de Sillos MD, Chiba SM, Soares ACF, Gomes CET, de Morais MB. Colonic transit time and fecal impaction in children and adolescents with cystic fibrosis-associated constipation. J Pediatr Gastroenterol Nutr. 2021;73(3):319–24.PubMedCrossRef

69.

Hedsund C, Gregersen T, Joensson IM, Olesen HV, Krogh K. Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol. 2012;47(8–9):920–6.PubMedCrossRef

70.

Hen J Jr, Dolan TF Jr, Touloukian RJ. Meconium plug syndrome associated with cystic fibrosis and Hirschsprung’s disease. Pediatrics. 1980;66(3):466–8.PubMed

71.

Esposito C, Sammarco G, De Fazio C, Alicchio F, Settimi A. Another case of cystic fibrosis complicated by meconium ileus associated with Hirschsprung’s disease: a rare and important association. Pediatr Surg Int. 2008;24(9):1069–71.PubMedCrossRef

72.

Stern RC, Izant RJ Jr, Boat TF, Wood RE, Matthews LW, Doershuk CF. Treatment and prognosis of rectal prolapse in cystic fibrosis. Gastroenterology. 1982;82(4):707–10.PubMedCrossRef

73.

Kulczycki LL, Shwachman H. Studies in cystic fibrosis of the pancreas; occurrence of rectal prolapse. N Engl J Med. 1958;259(9):409–12.PubMedCrossRef

74.

El-Chammas KI, Rumman N, Goh VL, Quintero D, Goday PS. Rectal prolapse and cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60(1):110–2.PubMedCrossRef

75.

Green J, Carroll W, Gilchrist FJ. Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis. Cochrane Database Syst Rev. 2018;8(8):CD012798.PubMed

76.

Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(Suppl 2):S24–8.PubMedCrossRef

77.

Taylor CJ, Aswani N. The pancreas in cystic fibrosis. Paediatr Respir Rev. 2002;3(1):77–81.PubMed

78.

McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018;315(5):G868–78.PubMedPubMedCentralCrossRef

79.

O’Brien CE, Anderson PJ, Stowe CD. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann Pharmacother. 2011;45(9):1061–6.PubMedCrossRef

80.

Benninga MA, Hussain SZ, Sood MR, Nurko S, Hyman P, Clifford RA, et al. Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension. Clin Gastroenterol Hepatol. 2022;20(3):602-10 e5.PubMedCrossRef

81.

Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38(4):341–51.PubMedPubMedCentralCrossRef

82.

Rao SSC, Quigley EMM, Chey WD, Sharma A, Lembo AJ. Randomized Placebo-controlled phase 3 trial of vibrating capsule for chronic constipation. Gastroenterology. 2023;164(7):1202-10 e6.PubMedCrossRef

Titel: Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract in Cystic Fibrosis
verfasst von: Dhiren Patel
Folashade Jose
Jason Baker
Baha Moshiree
Publikationsdatum: 07.12.2023
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 1/2024
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-023-00906-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen